Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of esafoxolaner eprinomectin and praziquantel topical solution in China. Welcome to wholesale bulk high quality esafoxolaner eprinomectin and praziquantel topical solution for sale here from our factory. Good service and reasonable price are available.
Esafoxolaner eprinomectin and praziquantel topical solution is a broad-spectrum antiparasitic topical drug designed specifically for cats, which combines three active ingredients to prevent and treat a variety of parasitic infections both inside and outside the body, including siphonapteras, ticks, roundworms, hookworms, heartworms, and tapeworms. It is highly effective, safe, and easy to use. It is the first and only broad-spectrum antiparasitic drug for cats that can simultaneously prevent and treat siphonapteras, ticks, roundworms, hookworms, heartworms, and tapeworms.
Comprehensive vermin protection can be provided through a one-time application, without the need for cat owners to use multiple medications simultaneously. The killing effect of this drug on adult siphonapteras can reach 92.1% to 99.7% within 24 hours after treatment, and the preventive effect remains above 95.5% in subsequent weekly reinfection for at least one month.
|
|
 |
| Esafoxolaner Eprinomectin And Praziquantel Topical Common specifications |
| (1)0.3ml:esafoxolaner 3.6mg+eprinomectin 1.2mg+praziquantel 24.9mg (1.8-5.5 lb) |
| (2)0.9ml:esafoxolaner 10.8mg+eprinomectin 3.6mg+praziquantel 74.7mg (5.6-16.5 lb) |
Esafoxolaner Eprinomectin And Praziquantel Topical COA
 |
||
| Certificate of Analysis | ||
| Compound name | Esafoxolaner Eprinomectin And Praziquantel Topical | |
| Grade | Pharmaceutical grade | |
| Quantity | Customized | |
| Packaging standard | Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090056 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure | N/A | |
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.27% |
| Loss on drying | ≤1.0% | 0.57% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.80% |
| Single impurity | <0.8% | 0.59% |
| Total microbial count | ≤750cfu/g | 102 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 621ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
Pet parasitic infections are one of the core challenges in global pet health management. Esafoxolaner eprinomectin and praziquantel topical solution, as the first broad-spectrum antiparasitic drug for cats, achieves synchronous prevention and control of siphonapteras, ticks, heartworms, roundworms, hookworms, and tapeworms through a single monthly use. The core breakthrough lies in the precise delivery mechanism of three active ingredients through the skin barrier.
Core Applications for Ectoparasite Control
Ectoparasite elimination is the primary and most advantageous application of this formulation. Relying on the potent insecticidal and repellent activity of its key active ingredient esafoxolaner, the product delivers powerful efficacy against common ectoparasites and blood-sucking arthropods infesting cats. It provides dual benefits of curing existing infestations and offering long-lasting protection against recurrence, boasting high clinical value.
Against Ctenocephalides felis (cat siphonaptera), the most prevalent ectoparasite in household and farm-raised cats, the product rapidly penetrates siphonaptera bodies and disrupts their nervous system, killing adult siphonapteras on the skin in a short time and immediately stopping fleas from blood-sucking and biting.Additionally, the drug forms a sustained-release film in the cat's sebaceous layer, which continuously inhibits siphonaptera egg hatching and larval development. This breaks the entire siphonaptera life cycle at the source and prevents repeated infestations.In terms of relieving clinical symptoms, the formulation thoroughly eradicates siphonaptera infestations and effectively alleviates allergic dermatitis triggered by siphonaptera bites.
It quickly eases typical manifestations including severe pruritus, local alopecia, skin erythema, papules and excessive dandruff, and reduces the risks of skin lesions and secondary bacterial infections caused by scratching.
For tick control, the product exerts strong lethal effects on various regional pathogenic ticks such as Ixodes persulcatus, Amblyomma americanum and Ixodes ricinus, meeting tick prevention demands for urban indoor cats, free-range outdoor cats and rescued stray cats. After transdermal absorption, the active ingredients stably reside on the skin surface and subcutaneous tissues.
The formulation takes effect quickly to kill attached and biting ticks, interrupt their blood-feeding process, and sharply cut down the incidence of severe infectious diseases transmitted by ticks, including haematozoon diseases, rickettsioses and babesiosis, thus protecting the feline haematological system and visceral organs.
Furthermore, this preparation is a first-line clinical medication for feline otodectic mange caused by Otodectes cynotis.
For mild to moderate ear mite infestations in cats, a single standard administration can rapidly kill mites in the ear canal and relieve typical symptoms such as accumulation of dark brown aural discharge, frequent head shaking and ear scratching, ear canal swelling, inflammation and foul odour. Continuous medication achieves a complete cure and prevents relapse. Featuring outstanding long-term efficacy against ectoparasites, a single dose remains effective for 30 days to defend against parasitic invasion, fully catering to the needs of regular monthly vermin prevention.
Clinical Applications for Endoparasite Prevention and Treatment
Combined with eprinomectin and praziquantel, two endoparasiticidal ingredients, esafoxolaner eprinomectin and praziquantel topical solution delivers comprehensive control over nematodes, tapeworms and trematodes in cats. It effectively alleviates physical damages and clinical symptoms induced by various endoparasitic infestations and improves sub-health conditions in cats.As a highly safe semi-synthetic avermectin derivative, eprinomectin has broad-spectrum activity against nematodes.
It efficiently eliminates major pathogenic nematodes in cats, such as Toxocara cati, Ancylostoma caninum, Ancylostoma tubaeforme and Capillaria aerophila. Kittens with weak immunity are highly susceptible to roundworm infections, which lead to abdominal distension, emaciation, inappetence and stunted growth. This formulation boasts a high cure rate for roundworm infestations in kittens. Its mild properties cause no obvious gastrointestinal irritation, making it well-suited for young cats.
Adult cats exposed to the external environment are prone to hookworm infections, which result in intestinal bleeding, anaemia and lethargy. The product quickly eradicates intestinal hookworms and repairs intestinal lesions caused by the vermins. Moreover, eprinomectin serves as a key ingredient for feline heartworm prevention. Its sustained efficacy blocks heartworm larval infections transmitted by mosquito bites, preventing feline heartworm disease fundamentally and avoiding life-threatening risks including cardiopulmonary damage and circulatory disorders. It is currently a core topical product for monthly heartworm prevention in cats.
The addition of praziquantel compensates for the deficiency of avermectins, which are ineffective against tapeworms and trematodes, expanding the endoparasiticidal spectrum of the formulation. Praziquantel specifically acts on the muscular and nervous systems of tapeworms and trematodes, triggering spasm, paralysis and death of the vermins. It thoroughly eliminates common pathogenic tapeworms in cats, including Dipylidium caninum, Taenia spp. and Diphyllobothrium latum. Tapeworm infestations damage the intestinal mucosa, cause chronic malnutrition, alternating diarrhoea and constipation, and passage of proglottids in faeces. Severe cases may lead to malnutrition, weight loss and declined immunity.
This formulation completely cures tapeworm infections, repairs intestinal tissues and restores normal digestive and absorptive functions. Meanwhile, praziquantel exerts prominent inhibitory and lethal effects on a variety of pathogenic trematodes, addressing occasional trematode infestations in cats.
The three active ingredients perform their respective functions and produce synergistic effects, realizing full-range and thorough control over both ectoparasites and endoparasites in cats.
It overcomes the drawbacks of traditional anthelmintics, such as narrow parasiticidal spectrum, separate medication requirements and incomplete vermin elimination, and adapts to complex clinical scenarios involving single or mixed parasitic infestations.
Overall, this compound topical spot-on solution containing esafoxolaner, eprinomectin and praziquantel adopts a scientifically formulated composition and advanced transdermal sustained-release technology, resolving multiple pain points of conventional pet anthelmintic products.
Representing technological advancement in the pet vermin control industry, the product targets three major categories of pathogenicvermins: ectoparasitic arthropods, intestinal nematodes, tapeworms and trematodes. It features a broad parasiticidal spectrum, rapid onset, long duration of action and excellent safety, applicable to regular parasite prevention for household pets, deworming for stray cat rescue, group vermin control in catteries and clinical treatment in veterinary hospitals.
Compared with traditional oral anthelmintics, this topical spot-on poses no risk of gastrointestinal irritation, and is suitable for special groups including kittens, senior cats and cats with sensitive digestive tracts, with lower administration barriers and wider adaptability. Regular and standardized use can effectively reduce the risk of parasitic infestations in cats, and prevent secondary diseases such as allergic dermatosis, intestinal disorders, anaemia and cardiopulmonary lesions caused by vermins, so as to fully safeguard the growth and general health of cats.
Thanks to its stable anthelmintic efficacy and high clinical safety, this compound spot-on has been widely recognized as a premium feline anthelmintic product across the global pet industry. It greatly improves the comprehensive prevention and control of parasitic diseases in cats, and holds irreplaceable value in pet health care and veterinary clinical practice.
Esafoxolaner eprinomectin and praziquantel topical solution is a combined spot-on formulation composed of esafoxolaner, eprinomectin and praziquantel. The three active ingredients are synthesized separately before compounding, with dimethyl isosorbide and glycerol formal serving as the mixed solvents.
Esafoxolaner (Isoxazoline class)
It is synthesized starting from 4-acetyl-1-naphthoic acid via condensation, cyclization and chiral resolution. Key procedures are as follows:
Condensation with 3-chloro-5-(trifluoromethyl)acetophenone to yield a ketone intermediate;
Addition reaction with hydroxylamine to construct the isoxazoline ring;
Chiral resolution to obtain the (S)-enantiomer with purity above 99.7%;
Amidation to link the trifluoroethylamide side chain. The overall yield is approximately 35%.
Eprinomectin (Avermectin class, semi-synthetic)
This product is derived from chemical modification of fermented avermectin B1.
Avermectin B1 is produced through fermentation by Streptomyces avermitilis;
The 4''-hydroxyl group is oxidized into a ketone group;
Reductive amination followed by acetylation introduces the 4''-acetamido group;
Separation of B1a and B1b isomers at a ratio of roughly 8:2 to improve safety for lactating animals.
Praziquantel (Pyrazinoisoquinoline class)
It is prepared via the classic Reissert reaction using isoquinoline as the starting material.
Reaction with acetyl chloride and sodium cyanide to form the Reissert intermediate;
High-pressure hydrogenation to reduce the cyano group;
Chloroacetylation and cyclization to build the parent ring structure;
Hydrolysis with phosphoric acid to generate primary amine;
Acylation with cyclohexanecarbonyl chloride to obtain the final product. The total yield is about 40%.
Formulation Compounding
The three active components are dissolved in anhydrous solvents at a concentration ratio of 12:4:83 mg/mL. Butylated hydroxytoluene (BHT) is added as an antioxidant. The finished product is obtained after sterile filtration and filling.
This combined formulation is developed by Boehringer Ingelheim and approved by the U.S. Food and Drug Administration (FDA) in 2019. It is a broad-spectrum spot-on endectocide exclusively for cats.
Esafoxolaner
Its development came amid the research boom of isoxazoline parasiticides. Boehringer Ingelheim discovered afoxolaner in 2008, which was launched commercially under the brand name NexGard in 2013. To adapt to feline spot-on preparations, the research team optimized its chiral structure between 2015 and 2018 and developed pure (S)-enantiomer esafoxolaner. Featuring enhanced skin permeability and a half-life of approximately 21.7 days, it is specially designed for feline medications.
Eprinomectin
As a member of the avermectin family, avermectin was discovered by Satoshi Ōmura and William Campbell in 1975, and the two scientists were awarded the Nobel Prize for this achievement in 2015. To address the issue of ivermectin residues in milk of dairy cows, Merck developed eprinomectin in 1990 by modifying the amino group at the 4'' position. This modification results in extremely low milk residues. The product was marketed as Eprinex in 1997 and later applied to companion animal vermin control.
Praziquantel
Praziquantel was jointly discovered by Bayer and Merck in Germany in the 1970s. Initially developed by Merck as a sedative, it was later found by Bayer to possess potent activity against tapeworms and flukes, with the code name EMBAY8440. It completed clinical validation in 1977 and was approved for the treatment of schistosomiasis in 1980, becoming the first-line drug for this disease. In veterinary medicine, it acts as a broad-spectrum anti-tapeworm agent and exerts synergistic effects with avermectins to target both endoparasites and ectoparasites.
Development of the Combined Formulation
After 2015, Boehringer Ingelheim integrated the three categories of active ingredients to develop the combined spot-on solution for cats. The product is effective against fleas, ticks, ear mites, heartworms, roundworms and tapeworms. Granted FDA approval in 2019 under the trade name NexGard Combo, it provides an all-in-one solution for feline vermin prevention and treatment.
FAQ
What is Esafoxolaner Eprinomectin?
+
-
The combination of esafoxolaner + eprinomectin + praziquantel (NexGard COMBO™) is a topical antiparasitic used to prevent heartworms and to prevent and treat intestinal parasites (hookworms, roundworms, and tapeworms), ear mites, fleas, and ticks (black-legged tick, lone star tick) in cats over eight weeks of age.
Hot Tags: esafoxolaner eprinomectin and praziquantel topical solution, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale